Strasbourg, France-based Aventis has announced its intention to
sell off part of its remaining stake in Rhodia, its loss-making
former specialty chemicals subsidiary. The move reduces its stake
in Rhodia to 15.3 per cent from 25.2...
As consolidation continues to mark the pharmaceutical industry,
more evidence to suggest that companies will increasingly turn to
biotechnology companies in order to gain the competitive edge comes
from a new study from Cutting Edge...
US company PPD is taking a stake in Chemokine Therapeutics, a
Canadian- and US-based biotechnology company, to continue
development of a proprietary peptide derived from a particular
chemokine that may make the peptide useful as a...
US provider of drug discovery tools Deltagen saw cutbacks in
workforce and the closure of operating units help boost revenue by
93 per cent for the fourth quarter of 2002 to $4.7 million (€4.3m),
compared to $2.5 million (€2.3m) for...
Total revenues for the four emerging sectors of protein array,
crucial antibody array, peptide biochip, protein biochip, and
solution bead/particle array were estimated at $90 million
(€83million) in 2002, writes market analyst Business...
Millipore, which specialises in providing technologies, tools and
services for the discovery, development and production of new
therapeutic drugs, has reported first-quarter 2003 sales of $187
million (€173 million), up 13 per cent...
UK biotechnology bellwether Celltech has emerged victorious in the
bidding battle for Oxford GlycoSciences. OGS reluctantly gave in to
Celltech's pressure on 11 April, after the latter firm bought
additional holdings which brought...
US Neuro Bioscience has signed an agreement to acquire a minimum of
75 per cent of the issued and outstanding share capital of CLL
Pharma, a French company engaged in the business of reformulating
drugs using its proprietary drug...